Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.

@article{Shahid2009BetalactamsAB,
  title={Beta-lactams and beta-lactamase-inhibitors in current- or potential-clinical practice: a comprehensive update.},
  author={Mohammed Shahid and Farrukh Sobia and A Singh and Anita C Malik and Haris Manzoor Khan and Daniel Jonas and Peter Hawkey},
  journal={Critical reviews in microbiology},
  year={2009},
  volume={35 2},
  pages={81-108}
}
The use of successive generations of beta-lactams has selected successive generations of beta-lactamases including CTX-M ESBLs, AmpC beta-lactamases, and KPC carbapenamases in Enterobacteriaceae. Moreover, this cephalosporin resistance, along with rising resistance to fluoroquinolones, is now driving the use of carbapenems and unfortunately the carbapenem resistance has emerged markedly, especially in Acinetobacter spp. due to OXA- and metallo-carbapenemases. The industry responded to the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS